We spoke to Professor Jean-François Obadia (Civils Hospices of Lyon, Lyon, France) about the 2-year follow up from the MITRA-FR trial, and how he would interpret the differing results from recent studies into the efficacy of the MitraClip in patients with mitral regurgitation. Finally, he touches on which patients might be likely to benefit from the intervention and how physicians can best identify them.
Speaker’s Disclosures: Jean-François Obadia has received research grants from Abbott and the French Ministry of Health and is a consultant for Dealcroix-Chevalier, Lanadanger, Medtronic, SJM (Abbott), Novartis and Sorin.
Questions:
1. What update can you provide from the 2-year follow up of the MITRA-FR trial? (0:05)
2. How would you interpret the differing results between recent studies into the efficacy of MitraClip in patients with mitral regurgitation? (1:00)
3. How can physicians identify patients most likely to benefit from this intervention? (1:44)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the European Society of Cardiology (ESC) Congress 2019 in Paris, France, September 2019.
